Penn Pharma Installs new Gerteis Roller Compactor Technology
Pharmaceutical manufacturer Penn Pharma has successfully installed a Gerteis Mini-Pactor at its contained manufacturing facility. This investment in new contained roller compaction technology will further expand its service offering at the award winning site in South Wales.
Penn Pharma, a PCI company, was proud to show off the installation of the new Mini-Pactor, which was successfully and safely maneuvered through a customised roof into the state-of-the-art contained manufacturing facility.
The Mini-Pactor was elevated and placed into position through the recently redesigned purpose-built flexible roof, fitted to allow the safe installation of this latest important technology.
Roller compaction is a process that provides a granulation method for materials that are heat and moisture sensitive, avoiding the use of liquid and high temperatures associated with wet granulation and subsequent drying methods. The Gerteis Mini-Pactor offers a patented, proven design that enhances powder flow as well as effective containment using skan isolator technology and integrated cleaning systems. The process is easily scaleable, facilitating shorter and less costly development programmes.
Bill Mitchell, CEO of parent company PCI, which acquired Penn in August 2014, was on site to oversee this latest milestone. Bill commented: “This latest investment is a further demonstration to our customers of the commitment we have made to deliver best in class solutions. This contained roller compactor increases our ability to provide advanced services in response to growing market demand for the processing and manufacturing of solid dosage forms containing potent molecules.
“The PCI Penn Tredegar site has more than 20 years of experience in the use of roller compactor technology. By combining expertise gained over time with state of the art technology, we understand the importance of this technology and its application in addressing the specific needs of our customers.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.